In theU.S., LYNPARZA has three approved indications in ovarian cancer: for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somaticBRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com...
In an interview withOncLive,Rogers, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the potential of ibrutinib in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field. What was ...
Head and Neck Squamous Cell Cancer KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck ...
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer Sa...
Elise AronitzEVERSANA, Burlington, ON, CanadaToby A. EyreOxford University Hospitals NHS Trust, Oxford, United KingdomMatthew Steven DavidsDana-Farber Cancer Institute, Boston, MAAmerican Society of Clinical OncologyJournal of Clinical Oncology